Low expression of SLC22A18 predicts poor survival outcome in patients with breast cancer after surgery

Cancer Epidemiology

Volumn 35, Issue 3, 2011, Pages 279-285

  He, Hongyu ^a   Xu, Cheng ^a   Zhao, Ziqin ^a   Qin, Xinyu ^a   Xu, Hongmei ^a   Zhang, Hongwei ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Breast neoplasm; Immunohistochemistry; Prognosis; SLC22A18; Survival analysis

Indexed keywords

MEMBRANE PROTEIN; SOLUTE CARRIER PROTEIN 22A18; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LOG RANK TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; REGRESSION ANALYSIS; SURVIVAL; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME;

BREAST NEOPLASMS; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANIC CATION TRANSPORT PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS;

EID: 79956057751     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2010.09.006     Document Type: Article

References (32)

1. Benson J.R., Jatoi I., Keisch M., Esteva F.J., Makris A., Jordan V.C. Early breast cancer. Lancet 2009, 373(9673):1463-1479.
2. Masood S. Prognostic/predictive factors in breast cancer. Clin Lab Med 2005, (25):809-825.
3. Jelinic P., Shaw P. Loss of imprinting and cancer. J Pathol 2007, 211(3):261-268.
4. Murrell A. Genomic imprinting and cancer: from primordial germ cells to somatic cells. Scientific World Journal 2006, 26(6):1888-1910.
5. Yamada H.Y., Gorbsky G.J. Tumor suppressor candidate TSSC5 is regulated by UbcH6 and a novel ubiquitin ligase RING105. Oncogene 2006, 25(9):1330-1339.
6. Schwienbacher C., Gramantieri L., Scelfo R., Veronese A., Calin G.A., Bolondi L., et al. Gain of imprinting at chromosome 11p15: a pathogenetic mechanism identified in human hepatocarcinomas. Proc Natl Acad Sci USA 2000, 97(10):5445-5449.
7. Lee M.P., Reeves C., Schmitt A., Su K., Connors T.D., Hu R.J., et al. Somatic Mutation of TSSC5, a novel imprinted gene from human choromsome 11p15.5. Cancer Res 1998, 58(18):4155-4159.
8. Tsuda H. Individualization of breast cancer based on histopathological features and molecular alterations. Breast cancer 2008, 15(2):121-132.
9. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L., et al. Human breast cancer: correlation of relapse and survival with amplificationof HER-2/neu oncogene. Science 1987, 235:177-182.
10. Masood S. HER-2/neu oncogene expression in atypical hyperplasia, carcinoma in stiu and invasive breast cancer. Mol Pathol 1991, 4(1):12A.
11. Tilghman S.M. The sins of the fathers and the mothers: genomic imprinting in mammalian development. Cell 1999, 96:185-193.
12. Armitage N.C., Davidson A., Tisikos D., Wood C.B. A study of the reliability of carcinoembryonic antigen blood levels in following the course of colorectal cancer. Clin Oncol 1984, 10:141-147.
13. Adriaenssens E., Dumont L., Lottin S., Bolle D., Leprêtre A., Delobelle A., et al. H19 overexpression in breast adenocarcinoma stromal cells is associated with tumor values and steroid receptor status but independent of p53 and Ki-67 expression. Am J Pathol 1998, 153(5):1597-1607.
14. Esteves L.I., Javaroni A.C., Nishimoto I.N., Magrin J., Squire J.A., Kowalski L.P., et al. DNA methylation in the CTCF-binding site I and the expression pattern of the H19 gene: does positive expression predict poor prognosis in early stage head and neck carcinomas?. Mol Carcinogen 2005, 44(2):102-110.
15. Ariel I., Sughayer M., Felling Y., Pizov G., Ayesh S., Podeh D., et al. The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma. Mol Pathol 2000, 53(6):320-323.
16. Douc-Razy S., Coll J., Barrois M., Joubel A., Prost S., Dozier C., et al. Expression of the human fetal BAC/H19 gene in invasive cancers. Int J Oncol 1993, 32:753-758.
17. Dugimont T., Curgy J.J., Wernert N., Delobelle A., Raes M.B., Joubel A., et al. The H19 gene is expressed within both epithelial and stromal components of human invasive adenocarcinomas. Biol Cell 1995, 85:117-124.
18. Douc-Razy S., Barrois M., Fogel S., Ahomadegbe J.C., Stéhelin D., Coll J., et al. High incidence of loss of heterozygosity and abnormal imprinting of H19 and IGF2 genes in invasive cervical carcinomas: uncoupling of H19 and IGF2 expression and biallelic hypomethylation of H19. Oncogene 1996, 12:423-430.
19. Liu J., Kahri A., Heikkilä P., Ilvesmäki V., Voutilainen R. H19 and insulin-like growth factor-II gene expression in adrenal tumors and cultured adrenal cells. J Clin Endocrinol Metab 1995, 80:492-496.
20. Walsh C., Miller S.J., Flam F., Fisher R.A., Ohlsson R., et al. Paternally derived H19 is differentially expressed in malignant and nonmalignant trophoblast. Cancer Res 1995, 55:1111-1116.
21. Kondo M., Suzuki H., Ueda R., Osada H., Takagi K., Takahashi T., et al. Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers. Oncogene 1995, 10:1193-1198.
22. Hibi K., Nakamura H., Hirai A., Fujikake Y., Kasai Y., Akiyama S., et al. Loss of H19 imprinting in esophageal cancer. Cancer Res 1996, 56:480-482.
23. Ariel I., Lustig O., Schneider T., Pizov G., Sappir M., De-Groot N., et al. The imprinted H19 gene as a tumor marker in bladder carcinoma. Urology 1995, 45:335-338.
24. Lottin S., Adriaenssens E., Dupressoir T., Berteaux N., Montpellier C., Coll J., et al. Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells. Carcinogenesis 2002, 23(11):1885-1895.
25. Kawamoto K., Onodera H., Kan S. Possible pararcrine mechanism of insulin-like growth factor-2 in the development of liver metastases from colorectal carcinoma. Cancer 1999, 85(1):18-25.
26. Randhawa G.S., Cui H., Barletta J.A., Strichman-Almashanu L.Z., Talpaz M., Kantarjian H., et al. Loss of imprinting in disease progression in chronic myelogenous leukemia. Blood 1998, 91(9):3144-3147.
27. Dao D., Frank D., Qian N., O'Keefe D., Vosatka R.J., Walsh C.P., et al. IMPT1, an imprinted gene similar to polyspecific transporter and multi-drug resistance genes. Hum Mol Genet 1998, 7(4):597-608.
28. Reece M., Prawitt D., Landers J., Kast C., Gros P., Housman D., et al. Functional characterization of ORCTL2--an organic cation transporter expressed in the renal proximal tubules. FEBS Lett 1998, 433(3):245-250.
29. Schwienbacher C., Sabbioni S., Campi M., Veronese A., Bernardi G., Menegatti A., et al. Transcriptional map of 170-kb region at chromosome 11p15.5: identification and mutational analysis of the BWR1A gene reveals the presence of mutations in tumor samples. Pro Natl Acad Sci USA 1998, 95(7):3873-3878.
30. Albrecht S., Hartmann W., Houshdaran F., Koch A., Gärtner B., Prawitt D., et al. Allelic loss but absence of mutation in the polyspecific gene BWR1A on 11p15.5 in hepatoblastoma. Int J Cancer 2004, 114(4):627-632.
31. Schwienbacher C., Gramantieri L., Scelfo R., Veronese A., Calin G.A., Bolondi L., et al. Gain of imprinting at chromosome 11p15: A pathogenetic mechanism identified in human hepatocarcinomas. Proc Natl Acad Sci USA 2000, 97(10):5445-5449.
32. Gallagher E., Mc Goldrick A., Chung W.Y., Mc Cormack O., Harrison M., Kerin M., et al. Gain of imprinting of SLC22A18 sense and antisense transcripts in human breast cancer. Genomics 2006, 88(1):12-17.